Aspell Niamh, Goldsteen Abigail, Renwick Robin
Innovation & Research, Trilateral Research Ltd., Waterford, Ireland.
Data Security and Privacy, IBM Research, Haifa, Israel.
Front Digit Health. 2024 Jan 31;6:1272709. doi: 10.3389/fdgth.2024.1272709. eCollection 2024.
This paper will discuss the European funded iToBoS project, tasked by the European Commission to develop an AI diagnostic platform for the early detection of skin melanoma. The paper will outline the project, provide an overview of the data being processed, describe the impact assessment processes, and explain the AI privacy risk mitigation methods being deployed. Following this, the paper will offer a brief discussion of some of the more complex aspects: (1) the relatively low population clinical trial study cohort, which poses risks associated with data distinguishability and the masking ability of the applied anonymisation tools, (2) the project's ability to obtain informed consent from the study cohort given the complexity of the technologies, (3) the project's commitment to an open research data strategy and the additional privacy risk mitigations required to protect the multi-modal study data, and (4) the ability of the project to adequately explain the outputs of the algorithmic components to a broad range of stakeholders. The paper will discuss how the complexities have caused tension which are reflective of wider tensions in the health domain. A project level solution includes collaboration with a melanoma patient network, as an avenue for fair and representative qualification of risks and benefits with the patient stakeholder group. However, it is unclear how scalable this process is given the relentless pursuit of innovation within the health domain, accentuated by the continued proliferation of artificial intelligence, open data strategies, and the integration of multi-modal data sets inclusive of genomics.
本文将讨论由欧盟资助的iToBoS项目,该项目由欧盟委员会委托开发一个用于早期检测皮肤黑色素瘤的人工智能诊断平台。本文将概述该项目,提供所处理数据的概述,描述影响评估过程,并解释所采用的人工智能隐私风险缓解方法。在此之后,本文将简要讨论一些较为复杂的方面:(1)相对较小的人群临床试验研究队列,这带来了与数据可区分性以及所应用匿名化工具的屏蔽能力相关的风险;(2)鉴于技术的复杂性,该项目从研究队列中获得知情同意的能力;(3)该项目对开放研究数据策略的承诺以及保护多模态研究数据所需的额外隐私风险缓解措施;(4)该项目向广泛的利益相关者充分解释算法组件输出的能力。本文将讨论这些复杂性如何引发了紧张关系,而这些紧张关系反映了健康领域更广泛的紧张状况。项目层面的解决方案包括与黑色素瘤患者网络合作,以此作为与患者利益相关者群体公平且具有代表性地评估风险和收益的途径。然而,鉴于健康领域对创新的不懈追求,由于人工智能的持续普及、开放数据策略以及包含基因组学的多模态数据集的整合而更加突出,目前尚不清楚这个过程的可扩展性如何。